Abstract: Provided are 5-membered heteroaryl-containing aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.

Abstract: A classification device and classification system for sorting and classifying bulb-type LED lighting through vision recognition from LED-mixed waste lighting having different forms of housing are provided. The classification device including: an input conveyor configured to move a plurality of LED-mixed waste lighting; a sensing part configured to obtain images of the LED-mixed waste lighting moving along a path of the input conveyor using a plurality of cameras; an analysis part configured to search for bulb-type LED lighting from the images obtained from the sensing part using an algorithm for image classification and recognition; a computation unit configured to calculate X, Y, and Z coordinate positions of an object classified as bulb-type LED lighting in the analysis part; and a conveying part configured to pick up and convey the object with the X, Y and Z coordinates calculated by the computation unit to a classifying conveyor.

Abstract: A classification device and classification system for sorting and classifying bulb-type LED lighting through vision recognition from LED-mixed waste lighting having different forms of housing are provided. The classification device including: an input conveyor configured to move a plurality of LED-mixed waste lighting; a sensing part configured to obtain images of the LED-mixed waste lighting moving along a path of the input conveyor using a plurality of cameras; an analysis part configured to search for bulb-type LED lighting from the images obtained from the sensing part using an algorithm for image classification and recognition; a computation unit configured to calculate X, Y, and Z coordinate positions of an object classified as bulb-type LED lighting in the analysis part; and a conveying part configured to pick up and convey the object with the X, Y and Z coordinates calculated by the computation unit to a classifying conveyor.

Abstract: A separator for a secondary battery, including: a porous polymer substrate having a plurality of pores; and a porous coating layer on at least one surface of the porous polymer substrate, the porous coating layer including a plurality of inorganic particles, a binder polymer and a urethane bond-containing crosslinked polymer. The binder polymer and the urethane bond-containing crosslinked polymer are on at least a part of the surface of the inorganic particles to connect and fix the inorganic particles with one another. The urethane bond-containing crosslinked polymer has a weight average molecular weight of 100,000-5,000,000, and the urethane bond-containing crosslinked polymer is present in an amount of 6 parts by weight to 60 parts by weight based on 100 parts by weight of the total weight of the binder polymer and the urethane bond-containing crosslinked polymer.

Abstract: The present invention relates to lipids for drug delivery, nanoparticles comprising same, and a composition for drug delivery comprising the nanoparticles. More specifically, the present invention relates to: lipids useful for drug delivery since the lipids can easily form a complex with an anionic drug due to a specific structure thereof, and the complex can be encapsulated inside nanoparticles formed by an amphiphilic block copolymer; nanoparticles comprising same; and a composition for drug delivery comprising the lipids and a composition for drug delivery comprising the nanoparticles.

Abstract: A seat adjustment apparatus for a vehicle includes a plurality of connection frames provided along two opposite sides of a seat frame and two opposite sides of a back frame and configured to move forward or rearward depending on a folding direction of the back frame, guide parts provided at middle points of the plurality of connection frames and configured to be moved upward or downward by forward or rearward movements of the connection frames, and a seat cushion pipe provided inside the two connection frames and configured such that front ends of the seat cushion pipe are connected to the guide parts, and a position of a rear end of the seat cushion pipe is adjusted upward or downward by upward or downward movements of the guide parts.

Abstract: A sheet frame module capable of forming an airtight line and flow path of reaction gas by bonding a plurality of sheet frames configured in a flat shape separately from a separator, and a unit cell for a fuel cell including the same, is disposed between a pair of separators for a fuel cell to form an airtight line and flow path of reaction gas, and includes a center sheet frame in which a membrane electrode assembly is disposed at a center portion thereof; a first side sheet frame disposed between one side of the center sheet frame and one of the pair of separators to form an airtight line and flow path of a first reaction gas; and a second side sheet frame disposed between the other side of the center sheet frame and another of the pair of separators to form an airtight line and flow path of a second reaction gas.

Abstract: A method is provided for producing a catalyst for oxygen reduction reaction in an electrochemical cell. The method for producing a catalyst for an oxygen reduction reaction of an electrochemical cell comprises preparing a solution containing sodium alginate and a solvent, preparing a gel by adding a transition metal precursor to the solution, preparing a reactant by adding a nitrogen doping agent to the gel, and stirring the reactant to cause a reaction to obtain a product; and heat-treating the product.

Abstract: The present disclosure relates to a pharmaceutical composition for preventing or treating statin-induced adverse effects or a pharmaceutical composition for co-administration with statin, the pharmaceutical composition containing, as an active ingredient, at least one selected from the group consisting of an isoprenoid-based compound, zaragozic acid, terbinafine, and ketoconazole. The pharmaceutical composition according to the present disclosure may prevent and/or treat adverse statin effects that can be induced by statin, that is, can be induced at any time by oxisterols present at abnormal levels in the body. The pharmaceutical composition can not only treat but also prevent the adverse effects of various statin therapeutics whose use has recently increased rapidly, and thus it is expected that the pharmaceutical composition can be widely used for various diseases and the utilization thereof can further be increased.

Abstract: Disclosed are an electrode gas diffusion layer assembly (EGA) and a fuel cell stack including the same. The content of the binder in the electrode and the content of the binder in the adhesive layer that attaches the electrode to the gas diffusion layer (GDL) may be optimized. Thus, it is possible to reduce the occurrence of flooding and the deterioration in durability/performance caused by a dry atmosphere in the EGA including the electrode and the adhesive layer, so that the output density per unit area is improved while the trade-off is minimized.

Abstract: The present disclosure relates to a pharmaceutical composition for preventing or treating statin-induced adverse effects or a pharmaceutical composition for co-administration with statin, the pharmaceutical composition containing, as an active ingredient, at least one selected from the group consisting of an isoprenoid-based compound, zaragozic acid, terbinafine, and ketoconazole. The pharmaceutical composition according to the present disclosure may prevent and/or treat adverse statin effects that can be induced by statin, that is, can be induced at any time by oxisterols present at abnormal levels in the body. The pharmaceutical composition can not only treat but also prevent the adverse effects of various statin therapeutics whose use has recently increased rapidly, and thus it is expected that the pharmaceutical composition can be widely used for various diseases and the utilization thereof can further be increased.

Abstract: Disclosed are an electrolyte membrane of a membrane-electrode assembly comprising a plasma-treated filler and a manufacturing method thereof The electrolyte membrane includes an ionomer having a membrane form and a filler dispersed in the ionomer and having a hydrophobic surface.

Abstract: Disclosed are an electrode gas diffusion layer assembly (EGA) and a fuel cell stack including the same. The content of the binder in the electrode and the content of the binder in the adhesive layer that attaches the electrode to the gas diffusion layer (GDL) may be optimized. Thus, it is possible to reduce the occurrence of flooding and the deterioration in durability/performance caused by a dry atmosphere in the EGA including the electrode and the adhesive layer, so that the output density per unit area is improved while the trade-off is minimized.

Abstract: A fuel cell system includes a fuel cell stack that produces electric power and water through an electro-chemical reaction of hydrogen and air. A controller of the fuel cell system calculates an amount of water in the fuel cell stack based on output power of the fuel cell stack and a maximum amount of residual water to which the amount of water in the fuel cell stack converges over time. The fuel cell system may detect the amount of water in the fuel cell stack in real time.

Abstract: The present disclosure relates to a pharmaceutical composition for preventing or treating statin-induced adverse effects or a pharmaceutical composition for co-administration with statin, the pharmaceutical composition containing, as an active ingredient, at least one selected from the group consisting of an isoprenoid-based compound, zaragozic acid, terbinafine, and ketoconazole. The pharmaceutical composition according to the present disclosure may prevent and/or treat adverse statin effects that can be induced by statin, that is, can be induced at any time by oxisterols present at abnormal levels in the body. The pharmaceutical composition can not only treat but also prevent the adverse effects of various statin therapeutics whose use has recently increased rapidly, and thus it is expected that the pharmaceutical composition can be widely used for various diseases and the utilization thereof can further be increased.

Abstract: A method of controlling the driving of a fuel cell system includes: determining whether the fuel cell system enters idle stop in which air supply to the fuel cell stack stops; dropping a DC-link terminal voltage controlled by a DC-DC converter up to a first set voltage by controlling an operation of the DC-DC converter connected to a DC-link terminal outputting generation power of the fuel cell stack at the time of entering the idle stop; and dropping a voltage of the fuel cell stack to reduce an oxide of platinum which is a catalyst of a fuel cell by allowing the anode exhaust gas to flow backward into a cathode of the fuel cell stack by performing the hydrogen purge in an idle stop state of opening the hydrogen purge valve after the voltage of the DC-link terminal drops.

Abstract: A fuel cell system includes a fuel cell stack that produces electric power and water through an electro-chemical reaction of hydrogen and air. A controller of the fuel cell system calculates an amount of water in the fuel cell stack based on output power of the fuel cell stack and a maximum amount of residual water to which the amount of water in the fuel cell stack converges over time. The fuel cell system may detect the amount of water in the fuel cell stack in real time.

Abstract: A method of controlling the driving of a fuel cell system includes: determining whether the fuel cell system enters idle stop in which air supply to the fuel cell stack stops; dropping a DC-link terminal voltage controlled by a DC-DC converter up to a first set voltage by controlling an operation of the DC-DC converter connected to a DC-link terminal outputting generation power of the fuel cell stack at the time of entering the idle stop; and dropping a voltage of the fuel cell stack to reduce an oxide of platinum which is a catalyst of a fuel cell by allowing the anode exhaust gas to flow backward into a cathode of the fuel cell stack by performing the hydrogen purge in an idle stop state of opening the hydrogen purge valve after the voltage of the DC-link terminal drops.

Abstract: The present invention provides a method for removing residual water in a fuel cell, which controls the humidity of purge gases to effectively remove residual water in the fuel cell and to maintain the humidity in a membrane at a constant level, thus ensuring the durability of the membrane. For this purpose, the present invention provides a method for removing residual water in a fuel cell, characterized in that the relative humidities of purge gases supplied to an anode and a cathode are controlled to selectively reduce water content in the fuel cell and water content in a membrane.

Abstract: The present invention provides a fuel cell bipolar plate in which an air gap or a material layer having a heat transfer coefficient lower than that of the bipolar plate is provided so as to reduce total amount of liquid water generated in a fuel cell, thereby preventing the occurrence of flooding and reducing the time required for cold start, enhancing durability, decreasing parasitic purge requirements, and enhancing operational stability.